This panel will explore the principles and critical importance of Relapsed/Refractory Multiple Myeloma (RR MM) in healthcare. Discussions will encompass current treatment standards, innovative advancements, and therapeutic comparisons. We will address existing challenges, propose strategic solutions, and examine emerging research and technological impacts. Attendees will leave with actionable insights, fostering collaboration and advancing the management of RR MM.